Voretigene Neparvovec: Side Effects, Uses & Monitoring

Facts extracted from current FDA product labeling for Voretigene Neparvovec. Educational only — not medical advice.

Labeled uses

LUXTURNA (voretigene neparvovec-rzyl) is an adeno-associated virus vector-based gene therapy indicated for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy. Patients must have viable retinal cells as determined by the treating physician(s).

Source: FDA labeling via NIH DailyMed (set 08313a24…). Not affiliated with FDA or NIH.

Medical disclaimer: Always consult a qualified healthcare professional about any medication.

Ratings summarize government-reported measures — they don't capture your personal needs. Visit the facility, ask about staffing and services, and use CMS checklists. This profile is informational only and is not a recommendation.